Cosentyx

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

https://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial

https://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasis

https://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

https://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/

Novartis trumpets long-term data for Cosentyx in psoriasis

https://pharmaphorum.com/news/novartis-trumpets-long-term-data-cosentyx-psoriasis/

Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS

https://pharmaphorum.com/news/imbruvica-opdivo-praluent-gain-approvals-scotlands-nhs/

Close in 10 seconds

Pharmaphorum.com

Search